ECSP10010105A - Antagonistas de cgrp - Google Patents
Antagonistas de cgrpInfo
- Publication number
- ECSP10010105A ECSP10010105A EC2010010105A ECSP10010105A ECSP10010105A EC SP10010105 A ECSP10010105 A EC SP10010105A EC 2010010105 A EC2010010105 A EC 2010010105A EC SP10010105 A ECSP10010105 A EC SP10010105A EC SP10010105 A ECSP10010105 A EC SP10010105A
- Authority
- EC
- Ecuador
- Prior art keywords
- salts
- cgrp antagonists
- hydrates
- diastereoisomers
- tautomers
- Prior art date
Links
- 229940127597 CGRP antagonist Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- 150000004677 hydrates Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002585 base Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Son objeto de la presente invención nuevos antagonistas de CGRP de la fórmula general (I) , (I)en la que U, V, X, Y, R1, R2 y R3 están definidos como se menciona en lo que sigue, sus tautómeros, sus isómeros, sus diastereoisómeros, sus enantiómeros, sus hidratos, sus mezclas y sus sales, así como los hidratos de las sales, en especial sus sales fisiológicamente compatibles con ácidos o bases inorgánicos u orgánicos, medicamentos que contienen a estos compuestos, su uso y procedimientos para su preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118811 | 2007-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010105A true ECSP10010105A (es) | 2010-06-29 |
Family
ID=39047647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010105A ECSP10010105A (es) | 2007-10-18 | 2010-04-14 | Antagonistas de cgrp |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8450327B2 (es) |
| EP (2) | EP2386558B1 (es) |
| JP (1) | JP5366960B2 (es) |
| KR (1) | KR20100091972A (es) |
| CN (1) | CN101827845A (es) |
| AU (1) | AU2008313733A1 (es) |
| BR (1) | BRPI0817835A2 (es) |
| CA (1) | CA2702503A1 (es) |
| CO (1) | CO6270226A2 (es) |
| EA (1) | EA201000612A1 (es) |
| EC (1) | ECSP10010105A (es) |
| IL (1) | IL204928A0 (es) |
| MA (1) | MA31782B1 (es) |
| MX (1) | MX2010003849A (es) |
| NZ (1) | NZ585347A (es) |
| TN (1) | TN2010000173A1 (es) |
| WO (1) | WO2009050234A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2065381A1 (de) * | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
| EP2225223B1 (de) * | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| CN102791692B (zh) * | 2010-03-12 | 2015-05-27 | 日本曹达株式会社 | 叔丁氧基羰基胺化合物的制造方法 |
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| KR102218333B1 (ko) | 2016-06-07 | 2021-02-22 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010042614A (ko) | 1998-04-10 | 2001-05-25 | 윌리암스 로저 에이 | 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체 |
| DE19911039A1 (de) | 1999-03-12 | 2000-09-14 | Boehringer Ingelheim Pharma | Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| DE19952147A1 (de) | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| MXPA03002263A (es) | 2000-09-14 | 2003-06-24 | Schering Corp | Antagonistas de receptor de neuropeptido y y5 de urea sustituidos. |
| US6831087B2 (en) | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
| ES2616539T3 (es) | 2002-06-05 | 2017-06-13 | Bristol-Myers Squibb Company | Antagonistas de receptores de péptidos relacionados con el gen de calcitonina |
| DE10250080A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US20050065144A1 (en) | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| DE102004018794A1 (de) * | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004018795A1 (de) | 2004-04-15 | 2005-10-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| JP2008512460A (ja) | 2004-09-08 | 2008-04-24 | メルク エンド カムパニー インコーポレーテッド | 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬 |
| JP2008512459A (ja) * | 2004-09-09 | 2008-04-24 | メルク エンド カムパニー インコーポレーテッド | アリールスピロラクタムｃｇｒｐ受容体拮抗薬 |
| EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| CA2609392A1 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| MX2007015705A (es) | 2005-06-29 | 2008-02-15 | Palau Pharma Sa | Derivados biciclicos como inhibidores de la cinasa p38. |
| DE102005050892A1 (de) | 2005-10-21 | 2007-04-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| WO2007133491A1 (en) | 2006-05-09 | 2007-11-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| WO2008070014A2 (en) | 2006-12-04 | 2008-06-12 | Neurogen Corporation | Biaryl ketone-substituted piperidines |
| WO2009034029A2 (de) | 2007-09-07 | 2009-03-19 | Boehringer Ingelheim International Gmbh | 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten |
| EP2065381A1 (de) | 2007-10-18 | 2009-06-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP Antagonisten |
| NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
| EP2225237A2 (de) | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2225223B1 (de) | 2007-11-22 | 2017-01-11 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| EP2062889A1 (de) | 2007-11-22 | 2009-05-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbindungen |
-
2008
- 2008-10-16 NZ NZ585347A patent/NZ585347A/en not_active IP Right Cessation
- 2008-10-16 JP JP2010529384A patent/JP5366960B2/ja active Active
- 2008-10-16 KR KR1020107010480A patent/KR20100091972A/ko not_active Withdrawn
- 2008-10-16 WO PCT/EP2008/063967 patent/WO2009050234A1/de not_active Ceased
- 2008-10-16 BR BRPI0817835 patent/BRPI0817835A2/pt not_active IP Right Cessation
- 2008-10-16 EP EP11176974.1A patent/EP2386558B1/de active Active
- 2008-10-16 EP EP08839172A patent/EP2205599B1/de active Active
- 2008-10-16 CA CA2702503A patent/CA2702503A1/en not_active Abandoned
- 2008-10-16 US US12/682,853 patent/US8450327B2/en active Active
- 2008-10-16 AU AU2008313733A patent/AU2008313733A1/en not_active Abandoned
- 2008-10-16 CN CN200880112297A patent/CN101827845A/zh active Pending
- 2008-10-16 EA EA201000612A patent/EA201000612A1/ru unknown
- 2008-10-16 MX MX2010003849A patent/MX2010003849A/es active IP Right Grant
-
2010
- 2010-04-08 IL IL204928A patent/IL204928A0/en unknown
- 2010-04-14 EC EC2010010105A patent/ECSP10010105A/es unknown
- 2010-04-16 TN TN2010000173A patent/TN2010000173A1/fr unknown
- 2010-04-16 CO CO10044754A patent/CO6270226A2/es not_active Application Discontinuation
- 2010-04-20 MA MA32781A patent/MA31782B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011500637A (ja) | 2011-01-06 |
| IL204928A0 (en) | 2010-11-30 |
| WO2009050234A1 (de) | 2009-04-23 |
| CN101827845A (zh) | 2010-09-08 |
| EP2205599A1 (de) | 2010-07-14 |
| US8450327B2 (en) | 2013-05-28 |
| EP2386558B1 (de) | 2014-10-01 |
| CA2702503A1 (en) | 2009-04-23 |
| NZ585347A (en) | 2011-09-30 |
| KR20100091972A (ko) | 2010-08-19 |
| BRPI0817835A2 (pt) | 2015-03-31 |
| EP2386558A1 (de) | 2011-11-16 |
| MA31782B1 (fr) | 2010-10-01 |
| AU2008313733A1 (en) | 2009-04-23 |
| CO6270226A2 (es) | 2011-04-20 |
| EP2205599B1 (de) | 2012-06-06 |
| JP5366960B2 (ja) | 2013-12-11 |
| TN2010000173A1 (fr) | 2011-11-11 |
| EA201000612A1 (ru) | 2010-10-29 |
| US20110172218A1 (en) | 2011-07-14 |
| MX2010003849A (es) | 2010-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29437A1 (es) | Nuevos antagonistas de cgrp | |
| CO6270226A2 (es) | Nuevos compuestos espirociclicos como antagonistas de cgrp | |
| UY28859A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento | |
| UY28040A1 (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos. | |
| UY30314A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
| CU23834B1 (es) | Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9 | |
| ECSP088194A (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos | |
| ECSP088638A (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
| ECSP12012161A (es) | Compuestos en calidad de antagonistas de Bradiquinina-b1 | |
| ECSP055747A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
| UY29176A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos. | |
| UY27722A1 (es) | Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimientos para su preparación. | |
| CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
| ECSP10010722A (es) | Compuestos orgánicos | |
| UY30979A1 (es) | Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos | |
| UY28848A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos | |
| DOP2011000176A (es) | Compuestos organicos | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| CO6331335A2 (es) | Nuevos compuestos antagonistas de los receptores b1 de bradiquinina | |
| UY29267A1 (es) | Derivados de piperidina y su uso como agentes antiinflamatorios | |
| CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
| CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
| UY31774A (es) | Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| ECSP078058A (es) | Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos |